Skip to main content

Oncolytic Polio Virus Vaccine Manufacturing and TechnologyTransfer from NCI

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
Jul 24, 2015
Award amount: 
Organization name: 
Duke University Medical Center
Principal Investigator: 
Herosian, Alan G.
Grant program category: 
Research and Equipment Support
Grant program name: 
Technology Enhancement Grant
Research Triangle

Duke investigators have developed a polio virus-based immunotherapy that is currently ending Phase 1 clinical studies for the treatment of recurrent glioblastoma, an aggressive brain cancer for which no effective treatment is available.  This treatment approach was recently featured on 60 Minutes.  TEG funding will be used to transfer the small-scale manufacturing of the vaccine from the NCI to a large-scale contract manufacturing facility. 

Fiscal year: